Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder
Molecules · 2024
DOI: 10.3390/molecules29050984 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Molecules, 2024. Verfasst von Marilyn A Huestis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA 19107, USA. Hauptthemen laut MEDLINE: Mitragyna, Secologanin Tryptamine Alkaloids. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson Foods, LLC, Johnson Foods, LLC..
Abstract (Originalsprache)
Kratom leaves, consumed by millions worldwide as tea or ground leaf powder, contain multiple alkaloids, with mitragynine being the most abundant and responsible for most effects. Mitragynine is a partial µ-opioid receptor agonist and competitive antagonist at κ- and δ-opioid receptors; however, unlike morphine, it does not activate the β-arrestin-2 respiratory depression pathway. Due to few human mitragynine data, the largest randomized, between-subject, double-blind, placebo-controlled, dose-escalation study of 500–4000 mg dried kratom leaf powder (6.65–53.2 mg mitragynine) was conducted. LC-MS/MS mitragynine and 7-hydroxymitragynine plasma concentrations were obtained after single and 15 daily doses. Mitragynine and 7-hydroxymitragynine Cmax increased dose proportionally, and AUC was slightly more than dose proportional. The median mitragynine Tmax was 1.0–1.3 h after single and 1.0–1.7 h after multiple doses; for 7-hydroxymitragynine Tmax, it was 1.2–1.8 h and 1.3–2.0 h. Steady-state mitragynine concentrations were reached in 8–9 days and 7-hydroxymitragynine within 7 days. The highest mean mitragynine T1/2 was 43.4 h after one and 67.9 h after multiple doses, and, for 7-hydroxymitragynine, it was 4.7 and 24.7 h. The mean 7-hydroxy-mitragynine/mitragynine concentration ratios were 0.20–0.31 after a single dose and decreased (0.15–0.21) after multiple doses. These mitragynine and 7-hydroxymitragynine data provide guidance for future clinical kratom dosing studies and an interpretation of clinical and forensic mitragynine and 7-hydroxymitragynine concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- PK Consultant, 50259 Pulheim, Germany.
- JB Pharma Consulting, 6418PR Heerlen, The Netherlands.
- Della Terra Pharmaceuticals, Atlanta, GA 30309, USA.
ORCID-Profile: Marilyn A Huestis, Martin A Brett
Förderung
- Johnson Foods, LLC
- Johnson Foods, LLC.
Zitieren
APA
Huestis, M. A., Brett, M. A., Bothmer, J., & Atallah, R. (2024). Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder. Molecules. https://doi.org/10.3390/molecules29050984
Vancouver
Huestis MA, Brett MA, Bothmer J, Atallah R. Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder. Molecules. 2024. doi:10.3390/molecules29050984
BibTeX
@article{Huestis2024,
author = {Huestis, Marilyn A and Brett, Martin A and Bothmer, John and Atallah, Ramsey},
title = {Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29050984}
}
EUVIMED